Minimally Invasive UroLift System Treatment Provides Rapid Symptom
Relief and Improved Quality of Life, While Preserving Sexual Function*1,2
WAYNE, Pa.--(BUSINESS WIRE)--Feb. 20, 2019--
Teleflex Incorporated (NYSE:TFX) today announced that 100,000 patients
have been treated globally with its minimally invasive UroLift®
System, a safe and effective treatment for men with Benign Prostatic
Hyperplasia (BPH) that provides rapid symptom relief and improved
quality of life while preserving sexual function.*1,2
BPH, also known as enlarged prostate, is a common condition marked by
bothersome urinary symptoms that can cause loss of productivity,
depression, interrupted sleep, and decreased quality of life.3
BPH affects over 40 million men in the United States alone.4
If left untreated, the condition can worsen over time and cause
permanent bladder damage.5
“We are extremely proud to see the vast number of patients that have
benefited from this minimally invasive technology, and we look forward
to helping even more men achieve the same rapid, durable relief from BPH
symptoms,” said Dave Amerson, president of the Teleflex Interventional
Urology Business Unit. “Reaching this milestone is a significant
achievement for not only the entire Interventional Urology team, but
also for the physicians who are committed to using the UroLift System to
provide exemplary care so that their patients can experience relief from
the burdensome symptoms of BPH.”
“The vast majority of patients with BPH are under the impression that
medication or invasive surgery are the only available options to treat
their symptoms; however, more and more physicians are recommending the
UroLift System treatment to their patients because it doesn’t carry the
long-term side effects of other BPH treatments,” said Peter Walter**,
M.D., F.A.C.S., of Western New York Urology Associates in Jamestown, NY.
“After treating men using the UroLift System and observing the positive
outcomes in their symptom relief and overall quality of life, I chose
the UroLift System as my own treatment for my BPH symptoms.”
“The UroLift System has become an accepted standard of care treatment
for men with enlarged prostate and the Prostatic Urethral Lift (PUL) is
now recommended by the American Urologic Association BPH Treatment
Guidelines,” said Steven Gange**, M.D., F.A.C.S., Summit Urology Group,
Salt Lake City, Utah. “The symptoms associated with enlarged prostate
can be extremely disruptive and burdensome, affecting the daily life of
men with this condition. Fortunately, the UroLift System treatment
allows men in diverse patient populations to experience significant
improvements in BPH symptoms while preserving their sexual function*1,2,
without requiring major surgery or the use of ongoing BPH medication.
The ultimate result is these patients return to a better quality of
life.”
*No instances of new, sustained erectile or ejaculatory dysfunction.
About the UroLift® System
The FDA-cleared UroLift System is a proven, minimally invasive
technology for treating lower urinary tract symptoms due to benign
prostatic hyperplasia (BPH). The UroLift permanent implants, delivered
during a minimally invasive transurethral outpatient procedure, relieve
prostate obstruction and open the urethra directly without cutting,
heating, or removing prostate tissue. Clinical data from a pivotal
206-patient randomized controlled study showed that patients with
enlarged prostate receiving UroLift implants reported rapid and durable
symptomatic and urinary flow rate improvement without compromising
sexual function. *1,2 Patients also experienced significant
improvement in quality of life. Over 100,000 men have been treated with
the UroLift System worldwide. Most common adverse events reported
include hematuria, dysuria, micturition urgency, pelvic pain, and urge
incontinence. Most symptoms were mild to moderate in severity and
resolved within two to four weeks after the procedure. The Prostatic
Urethral Lift procedure using the UroLift System is recommended for the
treatment of BPH in both the American Urological Association and
European Association of Urology clinical guidelines. The UroLift System
is available in the U.S., Europe, Australia, Canada, Mexico and South
Korea. Learn more at www.UroLift.com.
About Teleflex Interventional Urology
The Teleflex Interventional Urology Business Unit is dedicated to
developing innovative, minimally invasive and clinically effective
devices that address unmet needs in the field of urology. Our initial
focus is on improving the standard of care for patients with BPH using
the UroLift System, a minimally invasive permanent implant system that
treats symptoms while preserving normal sexual function. Learn more at www.NeoTract.com.
About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed to
improve the health and quality of people’s lives. We apply purpose
driven innovation – a relentless pursuit of identifying unmet clinical
needs – to benefit patients and healthcare providers. Our portfolio is
diverse, with solutions in the fields of vascular and interventional
access, surgical, anesthesia, cardiac care, urology, emergency medicine
and respiratory care. Teleflex employees worldwide are united in the
understanding that what we do every day makes a difference. For more
information, please visit www.Teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson
RCI®, LMA®, Pilling®, Rusch®,
UroLift® and Weck® – trusted brands united by a
common sense of purpose.
**Dr. Gange and Dr. Walter are paid consultants of Teleflex.
*No instances of new, sustained erectile or ejaculatory dysfunction
1 Roehrborn J Urol 2013 LIFT Study
2 McVary,
J Sex Med 2016
3 Speakman et al. 2014 BJUI International
4
Teleflex US Market Model estimates for 2018 based on IQVIA Health Drug
and Procedure data
5 Tubaro et al. 2003 Drugs Aging
MAC00970-01 Rev A
View source version on businesswire.com: https://www.businesswire.com/news/home/20190220005006/en/
Source: Teleflex Incorporated
For Teleflex Incorporated:
Jake Elguicze, 610.948.2836
Treasurer
and Vice President, Investor Relations
Media:
Nicole Osmer, 650.454.0504
nicole@healthandcommerce.com